1Turnbull F. Blood Pressure Lowering Treatment Trialists'Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectivelydesigned overviews of randomized trials [J]. Lancet, 2003, 362:1527-1535.
2Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report [J]. JAMA, 2003, 290:197.
3Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group[J]. Lancet, 1998, 351: 1755-1762.
4Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [J]. N Engl J Med, 2000, 342(3): 145-153.
5Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].Lancet, 2004, 363: 2022-2031.
6Sleight P, Yusuf S. New evidence on the importance of the reninangiotensin system in the treatment of higher-risk patients with hypertension [J]. J Hypertens, 2003, 21:1599-1608.
7Devereux RB, Dahlof B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with a tenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J]. Circulation, 2004, 110: 1456-1462.
8Nelson MR, Reid CM, Krum H, et al. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study(ANBP2) [J]. Am J Hypertens, 2003, 16:39-45.
9Coats AJ. Angiotensin receptor blockers-finally the evidence is coming in: IDNT and RENAAL[J]. Iht J Cardiol, 2001, 79(2-3):99-102.
10Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and nortality in hypertension: the Captopril Prevention Project (CAPPP)randomised trial [J ]. Lancet, 1999, 353: 611-616.
